A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
for Carcinoma, Transitional Cell
62 locations incl. Huntsville
Sponsor: Eli Lilly and Company
Sex: All·Age: 18+
Code: NCT07218380·Phase 3·Recruiting·Listed Oct 2025
UCLA Hematology/Oncology - Santa Monica
Clinical research site in Los Angeles, California
Part of UCLA
As of July 2026, 11 paid clinical trials are recruiting at UCLA Hematology/Oncology - Santa Monica in Los Angeles, California. Active studies at this site cover conditions such as Carcinoma, Transitional Cell, Urinary Bladder Neoplasms and Neoplasm Metastasis. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Recruiting clinical trials at UCLA Hematology/Oncology - Santa Monica (11)
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
for Carcinoma, Non-Small-Cell Lung
86 locations incl. Huntsville
Sponsor: Eli Lilly and Company
Sex: All·Age: 18+
Code: NCT06890598·Phase 3·Recruiting·Listed Mar 2025
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
for Metastatic Castration-resistant Prostate Cancer (mCRPC)
57 locations incl. Tucson
Sponsor: Merck Sharp & Dohme LLC
Sex: All·Age: 18+
Code: NCT06136650·Phase 3·Recruiting·Listed Nov 2023
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
for Prostate Cancer
49 locations incl. Phoenix
Sponsor: Merck Sharp & Dohme LLC
Sex: Male·Age: 18+
Code: NCT06925737·Phase 3·Recruiting·Listed Apr 2025
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
for Colorectal Cancer
32 locations incl. Chandler
Sponsor: Revolution Medicines, Inc.
Sex: All·Age: 18+
Code: NCT06445062·Phase 1, Phase 2·Recruiting·Listed Jun 2024
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
for Breast Cancer
22 locations incl. Duarte
Sponsor: Celcuity Inc
Sex: All·Age: 18+
Code: NCT06757634·Phase 3·Recruiting·Listed Jan 2025
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
for Relapsed or Refractory Multiple Myeloma (RRMM)
22 locations incl. Birmingham
Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Sex: All·Age: 18+
Code: NCT06615479·Phase 3·Recruiting·Listed Sep 2024
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
for Gastroesophageal Junction
6 locations incl. Tucson
Sponsor: Merck Sharp & Dohme LLC
Sex: All·Age: 18+
Code: NCT06445972·Phase 1, Phase 2·Recruiting·Listed Jun 2024
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
for Esophageal Squamous Cell Carcinoma
4 locations incl. Tucson
Sponsor: Merck Sharp & Dohme LLC
Sex: All·Age: 18+
Code: NCT05319730·Phase 1, Phase 2·Recruiting·Listed Apr 2022
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
for Gastroesophageal Junction
6 locations incl. Tucson
Sponsor: Merck Sharp & Dohme LLC
Sex: All·Age: 18+
Code: NCT06469944·Phase 1, Phase 2·Recruiting·Listed Jun 2024
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
for Prostatic Neoplasms, Castration-Resistant
5 locations incl. La Jolla
Sponsor: Merck Sharp & Dohme LLC
Sex: All·Age: 18+
Code: NCT06353386·Phase 1, Phase 2·Recruiting·Listed Apr 2024
More research sites in Los Angeles
- Cedars-Sinai Medical Center (227 trials)
- Children's Hospital Los Angeles (133 trials)
- University of California, Los Angeles (110 trials)
- University of Southern California (93 trials)
- Cedars Sinai Medical Center (68 trials)
- UCLA / Jonsson Comprehensive Cancer Center (67 trials)
- University of California Los Angeles (65 trials)
- USC / Norris Comprehensive Cancer Center (64 trials)
- UCLA (53 trials)
- USC Norris Comprehensive Cancer Center (53 trials)
Explore more
Paid clinical trials in Los Angeles, CA · California clinical trials